Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 24 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1986 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A INJ 3000000UNIT/VIAL (DIN 00705896) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in… | DIN00705896 | withdrawnsource: Cancelled Post Marketsince Jul 22, 1999 | health-canada-dpd |
| Dec 30, 1986 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A - KIT (PWS+DILUENT) 3000000IU/VIAL (DIN 02223384) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not… | DIN02223384 | withdrawnsource: Cancelled Post Marketsince Jul 11, 2000 | health-canada-dpd |
| Dec 30, 1986 | Etoposide | FDA US | Lung Small Cell Carcinoma | VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer— VePesid Capsules in combination with other approved… | ORIGNDA019557 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 1, 1986 | Valproic Acid | FDA US | cancer not stated in this record | Epilepsy Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 28, 1986 | Prednisolone | FDA US | cancer not stated in this record | Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1985 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE DBL INJ 2.5MG/ML (DIN 00614327) under ATC L01BA01 METHOTREXATE. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1984 | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUFLEX (DIN 00637726) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see… | DIN00637726 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1983 | Amsacrine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AMSA PD (DIN 00582212) under ATC L01XX01 AMSACRINE. Indications are not published in the Drug Product Database — see… | DIN00582212 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1982 | Vindesine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELDISINE INJ 5MG/2ML (DIN 00555665) under ATC L01CA03 VINDESINE. Indications are not published in the Drug Product… | DIN00555665 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1981 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as VEPESID INJ 20MG/ML (DIN 00523410) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product… | DIN00523410 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 13, 1981 | Azathioprine | FDA US | cancer not stated in this record | Efficacy supplement 1981-04-13 (see label) | SUPPLNDA016324 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1979 | Hydroxyurea | Health Canada CA | cancer not stated in this record | Marketed in Canada as HYDREA (DIN 00465283) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product Database… | DIN00465283 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1978 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRUCIL INJ 50MG/ML (DIN 00428493) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product… | DIN00428493 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 17, 1978 | Tretinoin | FDA US | cancer not stated in this record | Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this… | ORIGNDA017955 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1977 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE SODIUM INJ 20MG (DIN 00410195) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 7, 1977 | Carmustine | FDA US | cancer not stated in this record | Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1976 | Dacarbazine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DTIC DOME INJ 200MG/VIAL (DIN 00521183) under ATC L01AX04 DACARBAZINE. Indications are not published in the Drug… | DIN00521183 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 4, 1976 | Lomustine | FDA US | cancer not stated in this record | Brain Tumors Gleostine is indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical… | ORIGNDA017588 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1975 | Carmustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BICNU (DIN 00297763) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database — see… | DIN00297763 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| ORIGANDA070868 |
| approved |
| openfda |
| ORIGNDA019157 |
| approved |
| openfda |
| withdrawnsource: Cancelled Post Marketsince Aug 13, 1998 |
| health-canada-dpd |
| Dec 31, 1985 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON (DIN 00727695) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see… | DIN00727695 | withdrawnsource: Cancelled Post Marketsince Sep 14, 2022 | health-canada-dpd |
| Dec 31, 1985 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJ 0.5MG/ML (DIN 00644293) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN00644293 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1985 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHARMORUBICIN RDF INJ 50MG/VIAL (DIN 00640069) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN00640069 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1985 | Streptozocin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZANOSAR STERILE POWDER (DIN 00622141) under ATC L01AD04 STREPTOZOCIN. Indications are not published in the Drug… | DIN00622141 | withdrawnsource: Cancelled Post Marketsince Dec 19, 2017 | health-canada-dpd |
| Dec 31, 1985 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE DBL INJ 25MG/ML (DIN 00614343) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN00614343 | withdrawnsource: Cancelled Post Marketsince Aug 13, 1998 | health-canada-dpd |
| Dec 31, 1985 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE DBL INJ 10MG/ML (DIN 00614335) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN00614335 | withdrawnsource: Cancelled Post Marketsince Aug 14, 1997 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 1, 2015 |
| health-canada-dpd |
| Dec 31, 1984 | Teniposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as VUMON (DIN 00588989) under ATC L01CB02 TENIPOSIDE. Indications are not published in the Drug Product Database — see… | DIN00588989 | withdrawnsource: Cancelled Post Marketsince May 31, 2018 | health-canada-dpd |
| Dec 31, 1984 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as VEPESID (DIN 00616192) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see… | DIN00616192 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1984 | Mitomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MUTAMYCIN INJ 20MG/VIAL (DIN 00587710) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product… | DIN00587710 | withdrawnsource: Cancelled Post Marketsince May 29, 2006 | health-canada-dpd |
| Dec 31, 1984 | Vincristine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONCOVIN SOLUTION 1MG/ML (DIN 00611182) under ATC L01CA02 VINCRISTINE. Indications are not published in the Drug… | DIN00611182 | withdrawnsource: Cancelled Post Marketsince Aug 4, 1998 | health-canada-dpd |
| Dec 31, 1984 | Mitoxantrone | Health Canada CA | cancer not stated in this record | Marketed in Canada as NOVANTRONE INJ 2MG/ML (DIN 00614289) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug… | DIN00614289 | withdrawnsource: Cancelled Post Marketsince Aug 14, 1997 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 18, 2024 |
| health-canada-dpd |
| Dec 31, 1983 | Aminoglutethimide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTADREN TAB 250MG (DIN 00587729) under ATC L02BG01 AMINOGLUTHETIMIDE. Indications are not published in the Drug… | DIN00587729 | withdrawnsource: Cancelled Post Marketsince Aug 4, 1999 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 3, 2000 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 30, 2007 |
| health-canada-dpd |
| Dec 31, 1981 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE SODIUM INJ 25MG/ML (DIN 00519286) under ATC L01BA01 METHOTREXATE. Indications are not published in the… | DIN00519286 | withdrawnsource: Cancelled Post Marketsince Aug 14, 1997 | health-canada-dpd |
| Dec 29, 1981 | Cisplatin | FDA US | cancer not stated in this record | Efficacy supplement 1981-12-29 (see label) | SUPPLNDA018057 | approved | openfda |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 31, 1979 | Mitotane | Health Canada CA | cancer not stated in this record | Marketed in Canada as LYSODREN (DIN 00463221) under ATC L01XX23 MITOTANE. Indications are not published in the Drug Product Database — see… | DIN00463221 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 |
| health-canada-dpd |
| Dec 19, 1978 | Cisplatin | FDA US | Malignant Bladder Neoplasm | INDICATIONS Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination… | ORIGNDA018057 | approved | openfda |
| approved |
| openfda |
| withdrawnsource: Cancelled Post Marketsince Aug 14, 1997 |
| health-canada-dpd |
| Dec 31, 1977 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX PWS 500MG (DIN 00373753) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug… | DIN00373753 | withdrawnsource: Cancelled Post Marketsince Nov 17, 2000 | health-canada-dpd |
| Dec 31, 1977 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOSAR (DIN 00194727) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN00194727 | withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 | health-canada-dpd |
| Dec 31, 1977 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOSAR (DIN 00386715) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN00386715 | withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 | health-canada-dpd |
| Dec 31, 1977 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGACE (DIN 00386391) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database — see… | DIN00386391 | withdrawnsource: Cancelled Post Marketsince May 29, 2006 | health-canada-dpd |
| Dec 31, 1977 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOXAN TAB 25MG (DIN 00344877) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN00344877 | withdrawnsource: Cancelled Post Marketsince Nov 21, 2008 | health-canada-dpd |
| Dec 31, 1977 | Mitomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MUTAMYCIN INJ 5MG/VIAL (DIN 00381799) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product… | DIN00381799 | withdrawnsource: Cancelled Post Marketsince May 29, 2006 | health-canada-dpd |
| ORIGNDA017422 |
| approved |
| openfda |
| withdrawnsource: Cancelled Post Marketsince Sep 25, 1998 |
| health-canada-dpd |
| Dec 31, 1976 | Lomustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CEENU (DIN 00360430) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see… | DIN00360430 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1976 | Lomustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CEENU (DIN 00360422) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see… | DIN00360422 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1976 | Lomustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CEENU (DIN 00360414) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see… | DIN00360414 | withdrawnsource: Cancelled Post Marketsince Oct 1, 2019 | health-canada-dpd |
| Dec 31, 1976 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRIAMYCIN RDF INJ 10MG/VIAL (DIN 00357391) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug… | DIN00357391 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1976 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRIAMYCIN RDF INJ 50MG/VIAL (DIN 00353078) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug… | DIN00353078 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1976 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE SODIUM INJ 25.0MG/ML (DIN 00321397) under ATC L01BA01 METHOTREXATE. Indications are not published in the… | DIN00321397 | withdrawnsource: Cancelled Post Marketsince Aug 14, 1997 | health-canada-dpd |
| Dec 31, 1976 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOXAN TAB 50MG (DIN 00344885) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN00344885 | withdrawnsource: Cancelled Post Marketsince Jan 22, 2009 | health-canada-dpd |
| approved |
| openfda |
| Aug 4, 1976 | Lomustine | FDA US | Hodgkin Lymphoma | Hodgkin's Lymphoma Gleostine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma… | ORIGNDA017588 | approved | openfda |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 31, 1975 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as EFUDEX (DIN 00330582) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database —… | DIN00330582 | approvedsource: Marketed | health-canada-dpd |